<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01384409</url>
  </required_header>
  <id_info>
    <org_study_id>3357-006</org_study_id>
    <nct_id>NCT01384409</nct_id>
  </id_info>
  <brief_title>A Phase 3 Clinical Study of KW-3357 in Patients With DIC</brief_title>
  <acronym>3357-006</acronym>
  <official_title>A Clinical Study of KW-3357 in Patients Diagnosed as Disseminated Intravascular Coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of KW-3357 with concomitant use of heparin using
      multi-center, non-comparative, open-label method in patients diagnosed as disseminated
      intravascular coagulation (DIC) by Japanese Association for Acute Medicine-defined DIC
      criteria.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 days (or discontinuation)</time_frame>
    <description>Number of patients with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DIC resolution</measure>
    <time_frame>6 days (or discontinuation)</time_frame>
    <description>Japanese Association for Acute Medicine-defined DIC criteria score &lt; 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DIC score</measure>
    <time_frame>Screening, 2, 3, 4, 5, 6 days (or discontinuation)</time_frame>
    <description>Based on the Japanese Association for Acute Medicine-defined DIC criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ symptoms</measure>
    <time_frame>Screening, 4, 6 days (or discontinuation)</time_frame>
    <description>Sepsis related organ failure assessment score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity</measure>
    <time_frame>Screening, 4, 6 days (or discontinuation)</time_frame>
    <description>The Acute Physiology and Chronic Health Evaluation II score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma antithrombin activity</measure>
    <time_frame>Screening, 2, 3, 4, 5, 6 days (or discontinuation)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Disseminated Intravascular Coagulation (DIC)</condition>
  <arm_group>
    <arm_group_label>KW-3357</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KW-3357</intervention_name>
    <description>Intravenous infusion once a day</description>
    <arm_group_label>KW-3357</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese Association for Acute Medicine-defined DIC criteria score &gt;= 4

          -  Antithrombin activity &lt;= 70%

          -  Written informed consent from patient or guardian

        Exclusion Criteria:

          -  Anamnesis or complication of serious drug allergy

          -  Serious liver disorder, such as fulminant hepatitis and decompensated cirrhosis

          -  Pregnant, nursing, or possibly pregnant woman

          -  Possibility for the promotion of bleeding by concomitant use of heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2011</study_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

